Form 4: Bioventus Director Mary Kay Ladone Reports Stock Activity

Director Mary Kay Ladone exercised restricted stock units and received a new grant of equity in Bioventus Inc.

Summary

• Director Mary Kay Ladone acquired 32,282 shares of Class A Common Stock through the vesting of restricted stock units (RSUs) on June 2, 2026.
• Following the transaction, the director holds 111,263 shares of Class A Common Stock.
• The director was granted an additional 25,146 RSUs on June 3, 2026, which are scheduled to vest on the earlier of the next annual meeting or the first anniversary of the grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and equity ownership maintenance.

Positives

• Director maintains a significant equity stake of 111,263 shares, aligning interests with shareholders.

Negatives

• None identified.

Risks

• Vesting of new RSU grants is contingent upon the director continuing service on the Board of Directors.

Future Outlook

The director received a new grant of 25,146 RSUs that will vest on the earlier of the next annual meeting or June 3, 2027, provided the director remains in service.

Industry Context

StockSavvy.ai notes that routine equity compensation and vesting events for board members are standard corporate governance practices in the medical device sector, reflecting typical retention and incentive structures.

Comparison to Industry Standards

• The use of RSUs as a primary component of director compensation is consistent with standard practices among mid-cap medical technology companies.
• The vesting schedule aligns with typical one-year director equity grant cycles observed in the industry.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard equity-based compensation for a director.

Next Steps

• Vesting of the 25,146 RSUs granted on June 3, 2026, subject to continued board service.

Key Dates

Keywords

Bioventus, BVS, Insider Trading, Form 4, Equity Compensation, Director Ownership